Specialty
Program Manager - Prostate Cancer Supportive Care (PCSC) Program
Research Interests
- Prostate Cancer
- Testicular Cancer
- Clinical Trials
- Cancer Survivorship
- Health Economics
Contact Information
| phil.pollock@vch.ca | |
| Phone | 604-875-4111 ext. 22946 |
Personal Lab
Prostate Cancer Supportive Care (PCSC) Program
Publications
1. Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Sokal MP, Stenning SP, for the TE23 Trial Management Group and Collaborators and the NCRI Testis Cancer Clinical Studies Group. A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN53643604). Eur Urol (2014), http:// dx.doi.org/10.1016/j.eururo.2014.06.034. 2. Langley RE, Cafferty FH, Freeman SC, Pollock P, Jinks RC, Alhasso AA, Sundaram SK, Kockleburgh R, Rosen SD, Godsland IF, Clarke N, Kynaston HG, Parmar MK & Abel PD. Cardiovascular Outcomes in Prostate Cancer Patients Treated with LHRH Agonists or Transdermal Oestrogen in the Randomised Phase II PATCH Trial. Lancet Oncology (2013) Apr;14(4): 306-16. Epub 2013 Mar 4. DOI: 10.1016/S1470-2045(13)70025-1. PMID 23465742 3. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P & Stenning SP for the MRC TE19 and EORTC 30982 collaborators. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. (2011) Mar 10;29(8): 957-962. DOI: 10.1200/JCO.2009.26.4655 PMID 21282539 4. Mead GM, Fossa SD, Oliver TD, Joffe JK, Huddart RA, Roberts JT, Pollock P, Gabe R & Stenning SP. Randomized trials in 2466 patients with stage I seminoma: Patterns of relapse and follow-up. J Natl Cancer Inst. (2011) Feb 2;103(3) 241-49. DOI: 10.1093/jnci/djq525 PMID 21212385 5. Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M & Abel PD. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. (2008) Aug;102(4): 442-45. DOI 10.1111/j.1464-410X.2008.07583.x PMID 18422771. 1. Pollock PA, Ludgate A & Wassersug RJ. In 2124 half of all men can count on getting prostate cancer. Accepted for publication in Current Oncology, February 2015.
